The current status of irinotecan (CPT-11) in the United States

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 272-281

  Rothenberg, Mace L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC ALKALOID; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; STOMACH CANCER; UNITED STATES; UTERINE CERVIX CANCER; VOMITING;

EID: 0030465773     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26397.x     Document Type: Conference Paper

References (18)

1. ROTHENBERG, M. L., J. G. KUHN, H. A. BURRIS III, et al. 1993. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11: 2194-2204.
2. LESTINGI, T. M., E. E. VOKES, W. GRAY, R. L. SCHILSKY, et al. 1995. A phase I trial of CPT-11 in solid tumors with G-CSF and antidiarrheal support. Proc. Am. Soc. Clin. Oncol. 14: 480 (Abstract #1563).
3. GUPTA, E., T. M. LESTINGI, R. MICK, J. RAMIREZ, et al. 1994. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54: 3723-3725.
4. ROWINSKY, E. K., L. B. GROCHOW, D. S. ETTINGER, et al. 1994. Phase I and pharmacokinetic study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 54: 427-436.
5. ABIGEREGES, D., G. G. CHABOT, J. P. ARMAND, P. HÉRAIT, et al. 1995. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol. 13: 210-221.
6. ROTHENBERG, M. L., J. R. ECKARDT, J. G. KUHN, H. A. BURRIS III, et al. 1996. Phase II trial of irinotecan in patient with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol. 14: 1128-1135.
7. ABIGERGES, D., J. P. ARMAND, G. G. CHABOT, et al. 1993. High dose intensity of CPT-11 administered as single dose every 3 weeks: The Institut Gustave Roussy experience. Proc. Am. Soc. Clin. Oncol. 12: 133.
8. PITOT, H. C., D. WENDER, M. J. O'CONNELL, H. S. WIEAND & J. A. MAILLIARD. 1994. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group study. Proc. Am. Soc. Clin. Oncol. 13: 197 (Abstract #573).
9. CONTI, J. A., N. E. KEMENY, L. B. SALTZ, Y. HUANG, et al. 1996. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol. 14: 709-715.
10. KAVANAGH, J. J., A. P. KUDELKA, R. S. FREEDMAN, C. L. EDWARDS, et al. 1996. Phase II study of irinotecan (CPT-11) in refractory cervical cancer. Proc. Am. Soc. Clin. Oncol. 15: 281 (Abstract #758).
11. POTKUL, R. K., F. V. PRICE, H. BAILEY, M. GELDER, et al. 1995. Irinotecan (CPT-11) in advanced squamous cell carcinoma of the cervix (Phase II). Proc. Am. Soc. Clin. Oncol. 14: 279 (Abstract #785).
12. SHIMADA, Y., Y. SASAKI, K. SUGANO, et al. 1993. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion 5-fluorouracil in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 12: 196 (Abstract #575).
13. SHIMADA, Y., M. YOSHINO, A. WAKUI, et al. 1993. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. 11: 909-913.
14. SASAKI, Y., A. OHTSU, Y. SHIMADA, K. ONO & N. SAIJO. 1994. Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J. Natl. Cancer Inst. 86: 1096-1098.
15. SALTZ, L., J. KANOWITZ, N. KEMENY, D. KELSEN, et al. 1995. Phase I trial of irinotecan (CPT-11), 5-fluorouracil, and leucovorin in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 14: 476 (Abstract #1546).
16. DRENGLER, R., H. BURRIS, A. DIETZ, J. ECKARDT, et al. 1996. A phase I trial to evaluate orally administered irinotecan HCl (CPT-11) given daily x 5 every 3 weeks in patients with refractory malignancies. Proc. Am. Soc. Clin. Oncol. 15: 489 (Abstract #1560).
17. ROTHENBERG, M. L., D. A. RINALDI, L. S. SMITH, L. J. SCHAAF, et al. 1996. Every other week irinotecan (CPT-11): Results of a phase I and pharmacokinetic study. Proc. Am. Soc. Clin. Oncol. 15: 489 (Abstract #1561).
18. PITOT, H. C. IV, C. ERLICHMAN, R. M. GOLDBERG, J. M. REID, et al. 1996. Phase I trial of irinotecan (CPT-11) given once every three weeks to patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 15: 494 (Abstract #1581).